Article
Performance of PREMM5, clinical criteria, and immunohistochemistry for MMR proteins in genetic risk assessment of Mexican patients with colorectal cancer.
PloS one - 1 Jan 2026
Rodríguez-Olivares José Luis, Aguilar-Y-Méndez Dione, Kimball Tamara N, Rivero-García Pamela, Rios-Valencia Javier, Santuario-Facio Sandra, Rojas-Martinez Augusto, Ortiz-López Rocío, Barraza-Arellano Angélica Leticia, Aranda-Gutierrez Alejandro, Arteaga-Vazquez Jazmín, De-La-Mora-Molina Héctor, Herzog Josef, Jeter Joanne M, Weitzel Jeffrey N, Chávarri-Guerra Yanin
Abstract excerpt
BACKGROUND: All individuals with colorectal cancer (CRC) should undergo genetic cancer risk assessment given its implications for personalized treatment, surveillance, risk-reduction strategies, and cascade testing. Universal screening using immunohistochemistry (IHC) for mismatch repair (MMR) proteins in tumor tissue, when combined with clinical criteria, is essential for identifying individuals at higher risk...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
